Table 1.
Targeted therapies for solid tumours currently in clinical practice in France
| DCI | Targets | Indication |
|---|---|---|
| Anti angiogenics | ||
| Bevacizumab | VEGF | Renal carcinoma, Breast carcinoma, Colorectal carcinoma, Chest carcinoma. Glioblastoma |
| Sunitinib | VEGF-R, PDGF-R, c-Kit | Renal carcinoma, Thyroïd, Pancreatic endocrine tumor, Gastrointestinal stromal tumor |
| Sorafenib | VEGF-R, PDGF-R, c-Kit Raf | Liver carcinoma, Renal carcinoma |
| Regorafenib | VEGF-R, PDGF-R, c-Kit, FGF-R Raf | Colorectal carcinoma |
| Pazopanib | VEGF-R, PDGF-R, c-Kit | Renal carcinoma |
| Anti HER 1/HER 2 | ||
| Lapatinib | EGF-R HER2 | Breast carcinoma |
| Trastuzumab | HER 2 | Breast carcinoma, Gastric carcinoma |
| Erlotinib | EGF-R | Chest carcinoma, Pancreatic carcinoma |
| Gefitinib | EGF-R | Chest carcinoma |
| Cetuximab | EGF-R | Colorectal carcinoma, Head and neck carcinoma |
| Panitunumab | EGF-R | Colorectal carcinoma |
| mTOR Inhibitor | ||
| Temsirolimus | mTOR | Renal carcinoma |
| Everolimus | mTOR | Renal carcinoma, Endocrine tumor, Breast carcinoma |
| Others | ||
| Imatinib | c-Kit | Gastrointestinal stromal tumor |
| Olaparib | PARP | Ovarian cancer |
| Vemurafenib | Raf | Melanoma |
VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; HER, human epidermal growth factor receptor; mTOR, mammalian target of rapamycin; PARP, poly(adenosine diphosphate [ADP]–ribose) polymerase.